
Charles Darwin University

The importance of scabies coinfection in the treatment considerations for impetigo

Tasani, Monika; Tong, Steven Y C; Andrews, Ross M.; Holt, Deborah C.; Currie, Bart J.; Carapetis, Jonathan R.; Bowen, Asha C.

Published in:
Pediatric Infectious Disease Journal

DOI:
[10.1097/INF.0000000000001013](https://doi.org/10.1097/INF.0000000000001013)

Published: 04/03/2016

Document Version
Peer reviewed version

[Link to publication](#)

Citation for published version (APA):

Tasani, M., Tong, S. Y. C., Andrews, R. M., Holt, D. C., Currie, B. J., Carapetis, J. R., & Bowen, A. C. (2016). The importance of scabies coinfection in the treatment considerations for impetigo. *Pediatric Infectious Disease Journal*, 35(4), 374-378. <https://doi.org/10.1097/INF.0000000000001013>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

The Importance of Scabies Co-Infection in the Treatment Considerations for Impetigo

Monika Tasani, MBBS, FRACP^{1,2}, Steven Y.C. Tong, MBBS, FRACP, PhD^{2,3}, Ross M. Andrews, PhD³, Deborah C. Holt, PhD³, Bart J. Currie, MBBS, FRACP^{2,3}, Jonathan R. Carapetis, MBBS, FRACP, PhD^{4,5}, and Asha C. Bowen, MBBS, FRACP, PhD^{3,4,5}

¹ Royal Children's Hospital Melbourne, Victoria, Australia

² Royal Darwin Hospital, Darwin, Northern Territory, Australia

³ Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia

⁴ Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia

⁵ Princess Margaret Hospital for Children, Perth, Western Australia, Australia

Corresponding Author: Dr Asha C Bowen

Menzies School of Health Research

PO Box 41096 Casuarina NT 0811 AUSTRALIA

asha.bowen@menzies.edu.au

Abbreviated Title: Scabies Co-Infection and Impetigo Treatment

Running Head: Scabies and Impetigo Treatment

Keywords for index: Scabies, impetigo, scabies co-infection, treatment, remote communities

Disclosures: The authors have no conflict of interest or funding to disclose.

Acknowledgements: We thank the participants and their families who contributed to this trial in

the hope of finding a better treatment option for their sores. We thank Irene O'Meara as the project manager for this trial and Linda Ward for her assistance in statistical analysis.

ACCEPTED

Abstract

Background: Skin infections account for a high disease burden in Indigenous children living in northern Australia. Although the relationship between impetigo and scabies is recognised, the prevalence of scabies in children with impetigo is not well reported. We report the prevalence, demographics and treatment success outcomes of impetigo and scabies co-infection in Indigenous children who were participants in a randomized controlled trial of impetigo treatment conducted in remote communities of the Northern Territory, Australia.

Methods: Of 1715 screening episodes for impetigo, 508 children were randomized to receive intramuscular benzathinebenzylpenicillin (BPG), twice daily co-trimoxazole (SXT) for 3 days (4mg/kg trimethoprim plus 20mg/kg sulphamethoxazole per dose) or once daily co-trimoxazole (SXT) for 5 days (8mg/kg trimethoprim plus 40 mg/kg sulphamethoxazole per dose). A clinical diagnosis of scabies, tinea of the skin, scalp or nail, and head lice was made on all children. Scabies presence was not confirmed using diagnostic scrapings. In a post-hoc analysis, we determined whether co- infection with scabies had an impact on treatment success for impetigo.

Findings: Of children randomized to receive treatment for impetigo, 84/508 (16.5%) had scabies. The presence of scabies ranged from 14.3% to 20.0% in the three treatment groups. Treatment success for impetigo with and without scabies co- infection, independent of the treatment groups, was 75.9% and 86.6% respectively, absolute difference 10.7% (95% CI +1% to +21%). Treatment success for impetigo with and without scabies co-infection in the BPG group was 69.6% and 88.0% respectively, absolute difference 18.4% (95%CI -1 to +38%). In the pooled SXT groups the treatment success for impetigo with and without scabies co-infection was 78.6% and 86.0% with absolute difference 7.4% (95%CI -4 to +18%). Treatment success in

the pooled SXT group with scabies (78.6%) was higher than in the BPG group (69.6%) with scabies, absolute difference 9.0% (95% CI +0.1 to +18%). Prediction of treatment success for impetigo is dependent on the presence or absence of scabies and for scabies co-infected impetigo it was higher in the group treated with SXT.

Conclusions: The burden of scabies in an impetigo trial for Indigenous children was high. Treatment success for scabies co-infection was lower than for impetigo overall, with a higher success seen in the co-trimoxazole group than the benzylpenicillin group.

ACCEPTED

Introduction

Impetigo and scabies are the most common skin infections affecting Indigenous children and are endemic in the Top End of Australia. The prevalence of impetigo and scabies in children living in remote Australian Indigenous communities is very high and up to 10 – 70% at any one time¹⁻⁴ with the highest rates found in those living in the most disadvantaged settings⁵.

The worldwide prevalence of scabies⁴ and global epidemiology of impetigo³ have recently been reported from systematic reviews. These reviews found that scabies and impetigo are common problems in childhood in developing countries and in marginalized communities in high-income countries^{3,4} and are closely correlated³. Both studies found the highest burden in children from the Pacific region^{3,4}.

Scabies lesions are itchy and frequent scratching often results in secondary infection with bacterial pathogens^{6,7}. *Streptococcus pyogenes* is usually the primary pathogen in secondarily infected scabies⁸, while *Staphylococcus aureus* is often considered a co-colonizer. Streptococci and staphylococci have previously been isolated from mite faecal pellets resulting in the hypothesis that the mite itself can also contribute to the spread of the pathogenic bacteria⁹. In addition, scabies mites have recently been found to secrete proteins that have human complement inhibitory activity and these proteins have been reported to promote bacterial growth *in vitro*^{10,11}. Poor hygiene has also been postulated as an important risk factor in the development of streptococcal skin sepsis following scabies¹². Where tropical climates prevail, children with scabies are two to seven times more likely to have impetigo than children without scabies¹³.

Untreated scabies infestations may become secondarily infected, and result in serious invasive bacterial infections^{2,14,15}. In addition, once scabies lesions become infected with *S. pyogenes*, the host is at risk of the immunological consequences of *S. pyogenes* infection

including post-streptococcal glomerulonephritis and probably, acute rheumatic fever (ARF)¹⁴.

The burden of ARF and rheumatic heart disease (RHD) in the Indigenous population of Australia is amongst the highest reported in the world¹⁶ and streptococcal skin infections, driven at least in part by antecedent scabies, are considered a major contributor to this burden, even though the skin-throat- *S. pyogenes* –ARF immunopathogenetic pathways remain to be fully elucidated^{17,18}.

We describe the burden of scabies interacting with impetigo and treatment success from a randomized controlled trial (RCT) of the treatment of impetigo. Specifically, we:

- a) Describe the prevalence of scabies in Indigenous children who were screened for participation in the Skin Sore Trial⁷;
- b) Describe the demographics of those children randomized in the trial;
- c) Assess the impact that scabies presence had on treatment success in the Skin Sore Trial⁷;
and
- d) Assess for seasonal variation in the presence of impetigo and scabies.

Materials and Methods

Setting and Population

Indigenous children from seven remote communities in the Northern Territory were screened for participation in the Skin Sore Trial, described elsewhere⁷. Briefly, this large RCT compared two short courses of an oral antibiotic co-trimoxazole (SXT), against intramuscular injection of benzathine benzylpenicillin (BPG), the standard treatment for skin sores in our region. Intramuscular injection of benzathine penicillin is painful, which might deter parents and health-care providers from providing this treatment to children⁷. In addition, treatment adherence is higher with shorter duration of oral treatments¹⁹. There were 1715 children screened

by research nurses for skin sores at either the school, local health center, or at home and details recorded on the case report form (CRF). Participation in the Skin Sore Trial was permitted every 90 days, as skin sores recur and many children present for treatment of sores several times a year¹³. It was also postulated that the treatment effects of the regimens trialed would have no ongoing efficacy after the brief intervention (for oral antibiotics) and up to a maximum of one month (for intramuscular antibiotics). Of the screened participants, 508 children were randomized to participate over 663 enrolments. All analysis has been restricted to the child's first participation in the trial. This is a post-hoc analysis of the Skin Sore Trial⁷ with the focus on scabies. Recruitment took place in communities from the Top End and Central Australia. The Top End has a tropical climate divided into two dominant seasons, a wet season (November through April with maximal precipitation and high humidity) and a dry season (May through October with high daily temperatures, lower overnight temperatures and reduced humidity). Central Australia has a temperate, arid climate. Numbers were small from Central Australia, which precluded an analysis of the variation by season in this region.

Participants were randomized 1:1:1 to receive a single dose of intramuscular BPG or one of two short courses of oral SXT. These courses were either three days of twice daily SXT (4+20mg/kg/dose) or five days of once daily SXT (8+40mg/kg/dose). Trial participants were seen at baseline, day 2 and day 7 for skin sore swabs and photographs of the one (mild) or two sores (severe) under investigation⁷. Severity was stratified into mild impetigo, defined as one purulent or crusted sore and fewer than 5 sores in total or severe impetigo defined as >5 total body sores or ≥ 2 crusted or purulent sores. Treatment success was defined as any sore that was deemed to have improved or healed by day 7 when paired digital images of the sores were

viewed by expert assessors, blinded to treatment allocation^{7,20}. In participants with two assessed sores in the severe group, both were required to have been successfully treated.

Scabies assessments

At the initial screening visit, research nurses recorded the presence of impetigo, scabies, tinea of the skin, scalp or nail and headlice. In the subsequent enrolment visit, study staff recorded the presence of scabies, impetigo and whether the lesions were purulent or crusted. Research nurses were trained to screen and identify impetigo and scabies with a manual developed in previous work by the group^{7,21}. This training was overseen by the study doctor. Scabies presence was not confirmed using diagnostic scrapings. Children with clinically detected scabies (eg. pustules and impetigo that were associated with severe itch or presence of burrows) were provided with a scabicide cream (5% permethrin, Lyclear®) and verbal advice given on the appropriate use of the cream. While antibiotic treatment of impetigo was directly observed, there was no confirmation that the scabicide was applied.

Ethics statement

The Skin Sore Trial is registered (Australian and New Zealand Clinical Trials Registry N12609000858291) and was approved by the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research (09/08). Written informed consent was obtained from the parent or guardian of all participants.

Statistical analysis

Data were analyzed using STATA13 (Statacorp, College Station, TX). For categorical data, statistical significance was tested using Pearson's chi². For non-parametric data, statistical significance was tested using the Mann-Whitney test with $p < 0.05$ being considered significant.

Results

Over the 3-year study period, there were a total of 1715 screening episodes for inclusion. Data on the clinical detection of scabies was available for 1665/1715 (97.0%) screened children. Children with scabies were twice as likely to have impetigo that needed to be treated OR 1.9 (95% CI 1.4–2.6), $P < 0.0001$) than children without scabies (Table 1). Of those screened, 508 children (median age 7.0 years, 48.0 % females) were randomized into three treatment groups: 165 children to BPG, 175 children to twice daily SXT for 3 days (SXT 3) and 168 children to once daily SXT for 5 days (SXT 5). Two children randomized to the BPG group withdrew from the study before further data was collected. Baseline characteristics divided by the presence and absence of scabies are shown in Table 2. Scabies was diagnosed clinically in 84/508 (16.5%) participants. The presence of scabies ranged from 14.3% to 20.0% in the three treatment groups (Figure 1). Scabies was diagnosed in 35/184 (19.0%) children aged ≤ 5 years, 33/222 children (14.9%) aged 6–9 years and 16/100 children (16.0%) aged 10–13 years (no difference in scabies prevalence by age group, $p = 0.53$; Table 3). Children with scabies were more likely to have severe impetigo (88.1%) compared to those without scabies (68.5%) ($p < 0.01$). Children with scabies were more likely to have upper limb impetigo than those without scabies (38.4% vs 26.5%, $p < 0.01$) and less likely to have lower limb impetigo (38.4% vs 57.5%, $p < 0.001$).

Treatment success for impetigo with and without scabies co-infection, independent of the treatment groups was 75.9% and 86.6% respectively, absolute difference 10.7% (95% CI +1% to +21%, Table 4). Treatment success for impetigo with and without scabies co-infection in the BPG group was 69.6% and 88.0% respectively, absolute difference 18.4% (95%CI -1% to 38%). In the pooled SXT group the treatment success of impetigo with and without scabies co-infection was 78.6% and 86.0% with absolute difference 7.4% (95%CI -4% to +18%). Prediction of treatment success was dependent on the presence or absence of scabies (Table 4). Our previous study found no increased association between MRSA and scabies detection²².

Most children (463/508; 91.0%) were located in the tropical region, known as the Top End with (45/508; 9.0%) living in Central Australia, a desert climate. Scabies prevalence was 17.8% in the Top End and 16.5% in Central Australia, $p=0.47$.

The proportion of children from the Top End with scabies co-infection enrolled in the trial was not related to the season. There was no difference in the proportion with scabies in the dry versus the wet season ($p=0.47$).

Discussion

In this study we have documented the impact that scabies has on the severity of impetigo and the differential efficacy of impetigo treatment when scabies co-infection occurs. Our key findings are that there is a high burden of scabies in Australian Indigenous children who were screened and recruited into an impetigo trial, children with secondarily infected scabies tended to have more severe impetigo, are possibly less likely to respond to treatment with antibiotics than those without scabies, and that in the presence of scabies, treatment success may be more likely to be achieved when oral SXT is used rather than BPG.

Almost 17.0% of children recruited into the trial had secondarily infected scabies. This is similar to the reported prevalence of scabies in the region¹ and confirms the ongoing large disease burden of scabies and impetigo in Indigenous Australian children. Children who had scabies were more likely to have severe impetigo, which highlights the importance of addressing both the parasitic infestation and bacterial infection simultaneously. Although the prevalence of scabies in our study is high, it is similar to a national survey recently conducted in Fiji, which reported scabies prevalence of 18.5%. In their study, scabies was very strongly associated with impetigo contributing to 93.0% of the risk²³.

We have reported a significantly lower treatment success for participants with scabies infected impetigo than those without. In those without scabies, treatment success was achieved in 87.0%, which was similar to the overall treatment success for the impetigo trial of 85.0%. This suggests that the absence of scabies was associated with treatment success. While this may in part relate to the generally greater severity of impetigo in those with scabies, the potential adverse impact of scabies on local host innate immune responses to bacterial skin infection also needs consideration and further evaluation^{10,11,24}. In addition, there is a difference in treatment success between those treated with BPG and those treated with either of the two short courses of oral SXT. This post-hoc analysis warrants further investigation of the possible reasons for this. Early case reports did not confirm efficacy of SXT for the treatment of scabies²⁵. Despite this, SXT has activity against other parasites e.g. pediculosis²⁶ and further animal and human studies are needed to tease out this observation and whether SXT may have “mite killing” activity. It is unlikely that this difference in treatment success is driven by the presence of methicillin resistant *S. aureus* (MRSA) in children with scabies, as there was no increased association between MRSA and scabies detection observed in logistic regression models²². The only microbiological

association with the presence of scabies in the trial was an increased chance of detecting *S. pyogenes* (OR 2.2, 95% CI 1.1% – 4.4%)²⁰. Microbiology alone, cannot explain this difference in treatment success.

We found no difference in scabies prevalence by age group. This finding differs from a previous study in the same region that reported scabies to be more prevalent in children less than one year old²⁷, but is similar to the high scabies burden throughout childhood reported from Africa, South America and Fiji^{23,28,29}. In an impoverished community in rural Brazil, it was reported that the highest prevalence of scabies was in children four years or younger²⁸. In a study performed in Sierra Leone, the reported prevalence of scabies was as high as 77.0% in the under five year olds and up to 86.0% in the 5–9 year olds²⁹. In Fiji, it was reported that the prevalence of scabies was the highest in children between the ages of five to nine years²³. We have been unable to detect a difference in the rate of scabies by age group in this trial, although the majority of participants were aged between five and nine years, which is the peak period of impetigo occurrence¹⁴. The other possible reason why there was no difference in scabies prevalence by age group is that all the children recruited into the trial had impetigo, which in itself pre-selects for higher scabies prevalence.

Mite movements are temperature-dependent, with increased transmission of mites in a warm environment³⁰. Nevertheless a study in Malawi, which looked at the prevalence and seasonal associations of scabies and impetigo, found that scabies was more prevalent during the cold, dry season, most likely secondary to close interpersonal contact in crowded indoor environments. In contrast, there was an increase in the prevalence of impetigo during the wet season, which was attributed to poor hygiene³¹. In our study, we did not show a seasonal difference in impetigo or scabies.

The prevalence of scabies was 16.5% in this study, with inter-community variation. The range in prevalence was between 4.4% and 25.0%, with the highest rates found in two of the larger communities in the Northern Territory where overcrowding is especially common, with a median number of people per bedroom ranging between two and eight^{32,33}. This variation in scabies prevalence between communities is important to note, as it identifies communities where interventions may be of a higher priority.

Our study had several limitations. This is a post-hoc analysis of a randomized controlled, non-inferiority trial comparing two treatments for impetigo. While the presence of scabies mites was not confirmed using scrapings and microscopy, a clinical diagnosis remains the standard of care and our study used visual aids to train staff in making this diagnosis²⁰. Although scabies treatment was recommended for all children with scabies and permethrin provided, treatment was not directly observed. Randomization was not stratified by the presence of scabies. Despite this, the baseline characteristics of those with and without scabies were similar. Strengths of our study include the randomized controlled trial design with equal distribution of characteristics between treatment groups, a high prevalence of scabies which make our findings robust, and the consistent reporting of skin infections by research nurses trained in clinical assessments using a published manual with written and visual descriptions of sores and scabies²¹.

Acknowledgements

We thank the participants and their families who contributed to this trial in the hope of finding a better treatment option for their sores. We thank Irene O'Meara as the project manager for this trial and Linda Ward for her assistance in statistical analysis.

ACCEPTED

References

1. Andrews RM, Kearns T, Connors C, et al. A regional initiative to reduce skin infections amongst aboriginal children living in remote communities of the Northern Territory, Australia. *PLoS neglected tropical diseases*. 2009;3(11):e554.
2. Carapetis JR, Connors C, Yarmirr D, et al. Success of a scabies control program in an Australian aboriginal community. *The Pediatric infectious disease journal*. 1997;16(5):494-9.
3. Bowen AC, Mahe A, Hay RJ, et al. The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. *PLOS One*. 2015 Aug 28;10(8):e0136789.
4. Romani L, Steer AC, Whitfeld MJ, et al. Prevalence of scabies and impetigo worldwide: a systemic review. *Lancet Infectious Diseases*. 2015; Aug vol 15 (8); 960-967.
5. Andrews RM, McCarthy J, Carapetis JR, et al. Skin disorders, including pyoderma, scabies, and tinea infections. *Pediatric clinics of North America*. 2009;56(6):1421-40.
6. Shelby-James TM, Leach AJ, Carapetis JR, et al. Impact of single dose azithromycin on group A streptococci in the upper respiratory tract and skin of Aboriginal children. *The Pediatric infectious disease journal*. 2002;21(5):375-80.
7. Bowen AC, Tong SY, Andrews RM, et al. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. *Lancet*. 2014.
8. Steer AC, Tikoduadua LV, Manalac EM, et al. Validation of an Integrated Management of Childhood Illness algorithm for managing common skin conditions in Fiji. *Bulletin of the World Health Organization*. 2009;87(3):173-9.

9. McCarthy JS, Kemp DJ, Walton SF, et al. Scabies: more than just an irritation. *Postgraduate medical journal*. 2004;80(945):382-7.
10. Swe PM, Fischer K. A scabies mite serpin interferes with complement-mediated neutrophil functions and promotes staphylococcal growth. *PLoS Neglected Tropical Diseases*. 2014;8(6):e2928.
11. Mika A, Reynolds SL, Pickering D, et al. Complement inhibitors from scabies mites promote streptococcal growth--a novel mechanism in infected epidermis? *PLoS Neglected Tropical Diseases*. 2012;6(7):e1563.
12. Fischer K, Holt D, Currie B, et al. Scabies: important clinical consequences explained by new molecular studies. *Advances in parasitology*. 2012;79:339-73.
13. Kearns T, Clucas D, Connors C, et al. Clinic attendances during the first 12 months of life for Aboriginal children in five remote communities of northern Australia. *PloS One*. 2013;8(3):e58231.
14. Steer AC, Jenney AW, Kado J, et al. High burden of impetigo and scabies in a tropical country. *PLoS neglected tropical diseases*. 2009;3(6):e467.
15. Currie BJ, Carapetis JR. Skin infections and infestations in Aboriginal communities in northern Australia. *The Australasian journal of dermatology*. 2000;41(3):139-43; quiz 44-5.
16. Carapetis J SA, Mulholland E, Weber M. The global burden of group A streptococcal diseases. *Lancet infectious Diseases*. 2005;5:685-94.
17. McDonald MI, Towers RJ, Andrews RM, et al. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2006;43(6):683-9.

18. Carapetis JR, Walker AM, Hibble M, et al. Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. *Epidemiology and infection*. 1999;122(1):59-65.
19. Kemp K NT, Boswell J, Leach A, et al. Strategies for and problems associated with maximising and monitoring compliance with antibiotic treatment for otitis media with effusion in a remote Aboriginal community. *Aust J Rural Health*. 1994; 2: 25–31.
20. Bowen AC, Burns K, Tong SY, et al. Standardising and assessing digital images for use in clinical trials: a practical, reproducible method that blinds the assessor to treatment allocation. *PloS one*. 2014;9(11):e110395.
21. Menzies School of Health Research, Cooperative Research Centre for Aboriginal Health. Recognising and treating skin conditions. http://www.menzies.edu.au/icms_docs/162092_Recognising_and_Treating_Skin_Conditions.pdf (accessed July 26, 2014).
22. Bowen AC, Tong S, Chatfield MD, et al. The microbiology of impetigo in Indigenous children: associations between *Streptococcus pyogenes*, *Staphylococcus aureus*, scabies, and nasal carriage. *BMC infectious diseases*. 2014;14(1):3854.
23. Romani L, Koroivueta J, Steer AC, et al. Scabies and impetigo prevalence and risk factors in fiji: a national survey. *PLoS neglected tropical diseases*. 2015;9(3):e0003452.
24. Swe PM, Zakrzewski M, Kelly A, et al. Scabies mites alter the skin microbiome and promote growth of opportunistic pathogens in a porcine model. *PLoS neglected tropical diseases*. 2014;8(5):e2897.
25. Shashindran CH, Gandhi IS, Lal S. A trial of cotrimoxazole in scabies. *The British journal of dermatology*. 1979;100(4):483.

26. Flinders DC, De Schweinitz P. Pediculosis and scabies. *American family physician*. 2004;69(2):341-48.
27. Clucas DB, Carville KS, Connors C, et al. Disease burden and health-care clinic attendances for young children in remote aboriginal communities of northern Australia. *Bulletin of the World Health Organization*. 2008;86(4):275-81.
28. Feldmeier H, Jackson A, Ariza L, et al. The epidemiology of scabies in an impoverished community in rural Brazil: presence and severity of disease are associated with poor living conditions and illiteracy. *J Am Acad Dermatol*. 2009;60(3):436-43.
29. Terry BC, Kanjah F, Sahr F, et al. *Sarcoptes scabiei* infestation among children in a displacement camp in Sierra Leone. *Public Health*. 2001;115(3):208-11.
30. Commens CA. The treatment of scabies. *Australian Prescriber*. 2000;23(2).
31. Kristensen JK. Scabies and Pyoderma in Lilongwe, Malawi. Prevalence and seasonal fluctuation. *Int J Dermatol*. 1991;30(10):699-702.
32. McDonald E, Bailie R, Grace J, et al. A case study of physical and social barriers to hygiene and child growth in remote Australian Aboriginal communities. *BMC public health*. 2009;9:346.
33. Bailie RS, Stevens M, McDonald EL. The impact of housing improvement and socio-environmental factors on common childhood illnesses: a cohort study in Indigenous Australian communities. *Journal of epidemiology and community health*. 2012;66(9):821-31.

Figure 1: Flow chart of trial participants including the presence of scabies

ACCEPTED

Table 1. The presence and absence of scabies in participants screened for randomisation.

	Scabies positive		Scabies negative		Total
	n	%	n	%	
Sore requiring treatment *	154	64%	684	48%	838
Flat /dry or no sores	87	36%	740	52%	827
Total	241		1424		1665**

* Purulent or crusted sore

**Data on clinical detection of scabies was available for 1665/1715 screened children

ACCEPTED

Table 2. Distribution of study characteristics of trial participants based on presence or absence of scabies.

Variables	Scabies positive	Scabies negative	Total Study Cohort	P value
Female	44/84 (52.4%)	200/424 (47.2%)	244/508 (48.0%)	0.36
Median Age (y)	6.9 (5.7-8.1)	7.1 (6.9-7.5)	7.1	0.5
Severe Impetigo	74/84 (88.1%)	290/422** (68.7%)	364/506 (71.9%)	<0.01
Weight in kg (median)	20.8	20.6	20.4	0.5
Height in cm (median)	123	121	122	0.86
Household where other children also had sores (%)	44/84 (52.4%)	198/422** (46.9%)	242/506 (47.8%)	0.376
Location of sores*				
Upper limbs	63/159 (38.4%)	162/612 (26.5%)	213/771 (27.6%)	<0.01
Lower limbs	61/159 (38.4%)	352/612 (57.5%)	555/771 (72%)	<0.001

Other	35/159 (22.0%)	98/612 (16.0%)		
--------------	-------------------	-------------------	--	--

*Denominator larger because some children had more than one sore enrolled in the study.

** 2 children randomized in the study withdrew before any data was collected

ACCEPTED

Table 3. Scabies distribution by age group in children enrolled in the trial.

Age Group	Scabies positive n=84		Scabies negative n=422		P value
	n	%	n	%	
3m–5y (n=184)	35	19.0	149	81.0	0.525
6y–9y (n=222)	33	14.9	189	85.1	
10y–13y (n=100)	16	16.0	84	84.0	

ACCEPTED

Table 4. Intention to treat outcome.

Treatment Success	Scabies positive (Point Estimate)	95% CI	Scabies negative (Point Estimate)	95% CI
BPG (n=165)	69.6%	49.2%-89.9%	88.0%	82.3%-93.6%
SXT 3 (n=175)	81.8%	64.3%-99.3%	84.9%	78.9%-90.9%
SXT 5 (n=168)	76.5%	61.4%-91.4%	87.1%	81.4%-92.7%
Pooled SXT (n=343)	78.6%	67.5%-89.7%	86.0%	81.9%-90.1%
All patients (n=508)	75.9%	65.0%-84.9%	86.6%	82.9%-89.8%

ACCEPTED

Figure 1.

